Showing 2121-2130 of 3832 results for "".
- NYC Dermatologist Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://modernaesthetics.com/news/nyc-dermatologist-dr-doris-day-joins-nufabrxs-ad-board/2472988/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredient
- Here’s What’s Been Happening at Merz Aestheticshttps://modernaesthetics.com/news/heres-whats-been-happening-at-merz-aesthetics/2472979/Merz Aesthetics is launching its new “confidence to be” branding platform following the conclusion of the company’s reorganization. Merz is now three independently operating businesses: medical aesthetics, therapeutics and consumer care. “The new brand
- Industry Vet Didier Leclercq Joins Aerolase Leadership Teamhttps://modernaesthetics.com/news/industry-vet-didier-leclercq-joins-aerolase-leadership-team/2472958/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med onc
- Meet Cynosure’s Upgraded Elite iQ Aesthetic Workstationhttps://modernaesthetics.com/news/meet-cynosures-upgraded-elite-iq-aesthetic-workstation/2472944/Cynosure is launching the Elite iQ platform – the next generation of Cynosure’s Elite+ Aesthetic Workstation and the first Alexandrite-ND: YAG System to U.S., European and Australian mark
- Revance to Acquire HintMDhttps://modernaesthetics.com/news/revance-to-aquire-hintmd/2472941/Revance Therapeutics, Inc. has acquired HintMD, a financial technology platform for the aesthetics industry. Revance has agreed to pay HintMD’s shareholders a total of 8.54 million shares of Revance common stock, subject to customary adjustments provided in the acquisition agreeme
- David Long Tapped As Cynosure's Global Chief Financial Officerhttps://modernaesthetics.com/news/david-long-is-cynosures-global-chief-financial-officer/2472908/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its
- Cynosure Launches Potenza RF Microneedling Devicehttps://modernaesthetics.com/news/cynosure-launches-potenza-rf-microneedling-device/2472886/The U.S. Food and Drug Administration (FDA) cleared Cynosure’s Potenza, a four-mode radiofrequency (RF) microneedling device. The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz or 2 MHz frequency)
- RealSelf Reveals List of Most Worth It Procedureshttps://modernaesthetics.com/news/realself-reveals-list-of-most-worth-it-procedures/2472877/A total of 15 nonsurgical and 37 surgical procedures earned Real Self’s Most Worth It designation for 2020. The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as "Wo
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- It's A Deal: Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernaesthetics.com/news/its-a-deal-baring-private-equity-asia-agrees-to-acquire-lumenis/2472848/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <